Nanosphere, a nanotechnology-based molecular diagnostics company, has lined up $57 million in venture capital to commercialize a new and more efficient method for gene and protein testing. The company says its ultra-sensitive technology is able to look for minute levels of materials, helping to determine at an early stage if someone may be susceptible to disease. The technology was originally developed at the Nanotechnology Institute at Northwestern University. Bain Capital led the round for Nanosphere, which had earlier lined up $53 million in VC funds.
- read this article from the Chicago Sun-Times for more information
ALSO: Canada's Viron Therapeutics has raised $20 million in its first round. Release